FDA Approves Roche's OCREVUS ZUNOVO for Multiple Sclerosis Treatment

3 min read | September 16, 2024 09:41 AM BST | By Team Kalkine Media

In the healthcare sector, Swiss pharmaceutical company Roche has secured approval from the U.S. Food and Drug Administration (FDA) for its new treatment, OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq). This approval allows the use of OCREVUS ZUNOVO for both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), providing a new treatment option for individuals with these conditions. 

New Treatment for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic and debilitating disease affecting the central nervous system. It occurs when the immune system mistakenly attacks the protective layer surrounding nerve cells, leading to inflammation and damage that can cause a range of physical and neurological symptoms. MS is generally categorized into two forms: relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Both conditions require ongoing treatment to manage symptoms and slow disease progression. 

Roche (OTC:RHHBY)’s newly approved OCREVUS ZUNOVO is notable for being the first and only subcutaneous injection, administered by healthcare professionals twice a year, for both RMS and PPMS. This new injection takes approximately 10 minutes to administer, offering a more efficient option compared to other treatments that often require longer infusion times. 

FDA Approval Based on Positive Trial Data 

The FDA’s approval of OCREVUS ZUNOVO follows the results of the Phase III OCARINA II trial, which evaluated the safety and efficacy of this subcutaneous injection compared to the intravenous (IV) version of OCREVUS. The trial data showed no clinically significant differences in the blood levels of OCREVUS when administered subcutaneously versus intravenously. Importantly, the safety and efficacy profile of OCREVUS ZUNOVO was found to be consistent with the IV formulation in treating both RMS and PPMS. 

One area of note in the trial results was the occurrence of injection reactions. The safety profile of OCREVUS ZUNOVO largely mirrored that of the IV formulation, though injection reactions were more common, particularly with the first administration. 

Expanded Options for Multiple Sclerosis Patients 

Roche’s chief medical officer, Levi Garraway, highlighted the significance of this approval, noting that OCREVUS ZUNOVO provides both patients and healthcare providers with additional flexibility. With a decade of data supporting the safety and effectiveness of OCREVUS, this new formulation offers an alternative that may better suit the individual needs of patients with multiple sclerosis. The introduction of a subcutaneous option is likely to simplify treatment protocols and improve convenience for many patients.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next